Standard of Care Continues to Shift in RCC
Toni K. Choueiri, MD, discusses recent advancements and shares his insight on the future treatment landscape of patients with kidney cancer.
Frontline Treatment in Ovarian Cancer Could Undergo Transformation
Heather Dalton, MD, discusses the developing standard of care for the frontline treatment of patients with ovarian cancer.
Hamlin Discusses Practice-Changing Data in Lymphoma
Paul A. Hamlin, MD, discusses exciting updates from the 2017 ASH Annual Meeting throughout the large cell lymphoma space, as well as other advances on the horizon.
Following FDA Approvals, CML Pipeline Has Challenges
Michael J. Mauro, MD, discusses updates presented at the 2017 ASH Annual Meeting and the advances that are on the horizon for patients with chronic myeloid leukemia.
CAR T-Cell Therapy Starts to Enter MCL Space
Frederick L. Locke, MD, discusses the ongoing ZUMA-2 trial investigating axi-cel for patients with mantle cell lymphoma.
Expert Highlights Advances Across Lymphoma Subtypes
Alison J. Moskowitz, MD, discusses the latest treatment advances across subtypes of lymphoma.
Role of PARP Inhibitors in Breast Cancer Continues to Be Refined
Nadine M. Tung, MD, discusses the role of PARP inhibitors for patients with BRCA-positive breast cancer and the importance of genetic testing.
Diet Linked With Tumor Aggressiveness in Endometrial Cancer
Lindsay West, MD, discusses the relationship between low-fat or high-fat diets and endometrial cancer and how these can be investigated further.
PV Treatment Landscape Balancing Effective Regimens With QOL Challenges
Jeanne M. Palmer, MD, discusses the current treatment landscape for patients with polycythemia vera and highlighted the impact that ruxolitinib has had on the second-line treatment setting.
Giant of Cancer Care Shares Insights on Adjuvant Therapy in Melanoma
Adjuvant treatment of patients with intermediate- and high-risk melanoma has changed drastically in the past decade, according to John M. Kirkwood, MD.
Developments Expanding Frontline NSCLC Treatment
Thomas E. Stinchcombe, MD, discussea existing and emerging first-line regimens coming through the pipeline for the treatment of patients with non–small cell lung cancer.
Treatment Developments Shaking Up Landscape for Nonmetastatic CRPC
Mark J. Mann, MD, discusses the developing treatment landscape for patients with nonmetastatic CRPC.
Ongoing Trial to Determine Role of Degarelix in Lowering Cardiovascular AEs in Prostate Cancer
The ongoing phase IIIb PRONOUNCE trial is seeking to determine if the gonadotropin-releasing hormone receptor antagonist degarelix (Firmagon) is more likely to reduce cardiovascular events in patients with advanced prostate cancer and CVD versus the GnRH agonist receptor leuprolide.
New Agents on Horizon for HER2-Positive Breast Cancer
There are multiple therapeutic options in development for the treatment of patients with HER2-positive breast cancer, further adding to the regimens available, explains Frances Valdes-Albini, MD.
Expert Shares Treatment Updates for Neuroendocrine Tumors
The incidence of neuroendocrine tumors has increased 5-fold over the past 30 years, making it the second most prevalent diagnosis in gastrointestinal (GI) malignancies.
Pegram Highlights Progress in HER2+ Breast Cancer
Mark D. Pegram, MD, discusses the evolving treatment paradigm of HER2-positive breast cancer.
Treatments Emerging to Combat Endocrine Resistance in ER+ Breast Cancer
Heather Han, MD, discusses emerging approaches for combating endocrine resistance in patients with ER-positive breast cancer.
Expert Reviews CLL Advances Presented at ASH
Alan Skarbnik, MD, shares his insight on the latest updates in chronic lymphocytic leukemia presented at the 2017 ASH Annual Meeting.
Bekaii-Saab Highlights Emerging Agents in Pancreatic Cancer Pipeline
Tanios Bekaii-Saab, MD, discusses emerging treatments offering hope to patients with pancreatic cancer.
Precision Medicine Impact Grows in GI Cancer Paradigm
Bert H. O’Neil, MD, discusses the role of molecular testing throughout GI cancers and highlights the current and developing treatment landscape for patients with colorectal cancer.
Benefit of Elacestrant Improves With Longer Duration of CDK4/6 Inhibition in Patients With ER+/HER2– Metastatic Breast Cancer
Lifileucel Induces Response in Metastatic Melanoma Independent of Number of IL-2 Doses Received
Rajkumar Previews CAR-T Updates, Elranatamab Findings in Multiple Myeloma Ahead of ASH 2022
Palbociclib Plus Fulvestrant Fails to Improve PFS in ER+/HER2- Breast Cancer After Progression on a CDK4/6 inhibitor
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.